A series of peptide NK2 receptor agonists was evaluated for affinity, potency, efficacy, and selectivity at human recombinant NK2 and NK1 receptors expressed in CHO cells to identify compounds with the greatest separation between NK2 and NK1 receptor agonist activity. Binding studies were performed using displacement of [ ]-NKA(4-10) (ratio = 74), and NKA exhibited marginal selectivity (ratio = 2.8).
had the greatest selectivity for activation of NK2 over NK1 receptors (NK1/NK2 EC 50 ratio = 244), followed by [Lys
Introduction
Agonists acting at tachykinin NK2 receptors have potential as a new class of therapeutics to stimulate bladder and rectal voiding 'on demand' in patients with impaired voluntary control over urination and defecation. The ability of the endogenous peptide, neurokinin A (NKA), and other NK2 agonists, to contract bladder and colon smooth muscle preparations from various species (including human) has been amply documented [1] [2] [3] [4] [5] . Administration of NK2 agonists to anesthetized animals increases bladder tone, contractility, and distension-evoked responses [6] [7] [8] [9] , and increases gastrointestinal motility [10, 11] and colorectal pressure [8, 9, 12] . a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
The rapid inactivation of NKA and related peptides by protease enzymes in vivo means that on-demand voiding may be completed rapidly, with no residual contractile activity until the next on-demand administration. However, a significant limitation of peptide NK2 agonists is their poor selectivity for NK2 over NK1 receptors. Despite its weak ability to displace radiolabeled substance P from recombinant NK1 receptors, NKA is a potent NK1 receptor agonist in functional assays and binds with subnanomolar affinity to a septide-sensitive site on NK1 receptors [13] [14] [15] . Activation of NK1 receptors by NKA and related analogs can cause unwanted effects including hypotension [9, 12, 16] and emesis [17] , and so it is important to identify NK2 agonists with a high degree of selectivity for NK2 receptors over septide-sensitive sites on NK1 receptors.
The present studies characterized a series of peptide agonists to explore how various structural changes influence NK2 receptor affinity, potency, efficacy and selectivity. It is known that the truncated peptide, NKA(4-10), has greater potency for NK2 receptors, and that substitution of Met 10 with Nle yields a more selective but less potent agonist than NKA [18] . Other substitutions that improved potency and selectivity were replacing Ser 5 with Arg [19] , or Lys [20] , replacing Gly 8 with β-Ala [21] , and Leu 9 with MeLeu [22] . Multiple substitutions, such as (4) (5) (6) (7) (8) (9) (10) , also conferred greater potency, but not affinity [20, 22] . A limitation of these studies is that they employed native tissues that are not pure monoreceptor systems, and so interpretation is complicated by the presence of other receptors (including NK1) that may contribute to NK2 receptor-mediated responses [18, 20] . They also did not examine the effects of these modifications on affinity and agonist efficacy at the septide site on NK1 receptors. The present studies extend these observations by using recombinant cell lines expressing either human NK2 or NK1 receptors for radiolabeled binding and functional studies. Substitutions known to improve potency were used as a basis to examine additional modifications, generating novel peptides that were not previously studied. The effects of these amino acid modifications on the potency and affinity of the peptides for the septide site of the NK1 receptor were also examined for the first time.
Materials and methods

Materials
NKA and the peptide analogs of NKA listed in Table 1 were synthesized by Genscript (Piscataway, USA) to a purity �95%. NKA and substance P were purchased from Sigma Aldrich, (St. Louis, USA); septide was purchased from Bachem (Bubendorf, Switzerland, EU 
Cell cultures
Human recombinant NK2 and NK1 receptors were generated using stably transfected CHO cells (CHO-hNK2 and CHO-hNK1, respectively). Human NK2 or NK1 receptor expressing vectors from Genecopeia (Rockville, USA) were transfected in CHO cells using the standard FuGENE protocol and cells were selected using 450 μg/mL geneticin (G418). Clones expressing the receptors were selected by functional coupling to calcium using FLIPR and a single clone for each receptor subtype was selected for expansion and stable cell line generation. Cells were cultured in a humidified incubator with 5% CO 2 in F12K medium containing 10% heat inactivated FBS and 450 μg/mL geneticin and passaged on reaching 80-90% confluence.
Radioligand binding
Membrane preparation. Protein expression was induced by addition of 5 mM sodium butyrate to the culture medium. After 16 h, the medium was removed and the cells were washed with PBS (calcium and magnesium-free) and detached. The cell suspension was collected, placed on ice and centrifuged for 5 min at 4˚C and 1200 rpm in a Beckman GS6R centrifuge. After removal of the supernatant the cell pellet was washed and collected by resuspension in PBS and centrifugation. The final pellet was weighed and frozen at -80˚C until use.
Frozen pellets were thawed and homogenized in 10 volumes (w/v) of membrane preparation buffer (50 mM HEPES pH 7.4, 1 mM EDTA, 50 μg/mL bacitracin and protease inhibitors) using a Polytron Ultraturrax (twice for 15 s per cycle). The homogenate was centrifuged for 20 min at 4˚C and 18500 rpm in a SL-50T Sorvall rotor and the pellet was re-suspended in membrane preparation buffer and re-homogenized as before. After centrifugation for 20 min at 4˚C and 18500 rpm, the pellets were re-suspended in 5 volumes of membrane preparation buffer and divided into aliquots before freezing at -80˚C. Protein concentration was determined using BioRad Protein Assay (Milan, Italy) with a BSA standard curve.
Filtration assays. Stock solutions of test compounds (10 mM) were prepared in DMSO and stored at -20˚C until use. Further dilutions were performed in DMSO to provide an 11-point concentration response curve spanning final concentrations from 0.01 nM to 10 μM. Radioligand binding experiments were performed immediately after transferring 2 μL of each concentration of test compound to a 96-well plate. Each well contained a final volume of 200 μL buffer (50 mM HEPES, 3 mM MnCl 2 , 0.02% BSA, 0.02% Pluronic F-127 and 50 μg/mL ]-Septide saturation curve) were stopped by rapid filtration through Unifilter-96 GF/C filter plates pre-soaked for one hour in 0.5% PEI followed by 3 washings with 1 mL ice-cold 0.9% NaCl using a Packard cell harvester. After drying for 1 h at 40˚C, 50 μL of Microscint-20 was added to each filter plate and bound radioactivity was measured using a Microplate TopCount (Packard C9912). 
Functional assays
Intracellular calcium response. The agonist efficacy of the test compounds at recombinant human NK1 or NK2 receptors expressed in CHO cells was assessed by measuring the intracellular calcium response using the calcium-sensitive dye Fluo-4 AM (Eugene, OR, USA) and a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, CA, USA). CHO-hNK1 and CHO-hNK2 cells were seeded into black walled clear-bottom 384-well plates at a density of 10,000 and 15,000 cells per well in 50 μL culture media, respectively, and grown overnight at 37˚C in a humidified CO 2 -incubator. Cells were washed in washing buffer using an EMBLA 384 plate washer, leaving 20 μL of buffer per well after the final aspiration. Cells were then incubated at 37˚C with the cytoplasmic Ca 2+ indicator Fluo-4 AM (final concentration 1 μM)
in assay buffer (20 mM HEPES, 145 mM NaCl, 5 mM KCl, 5.5 mM glucose, 1 mM MgCl 2 and 2 mM CaCl 2 , pH 7.4, 0.05% Pluronic F-127 and 0.1% BSA) containing 2.5 mM probenecid for 45-60 min (cell loading). Cells were then washed 3 times in washing buffer (20 mM HEPES, 145 mM NaCl, 5 mM KCl, 5.5 mM glucose, 1 mM MgCl 2 and 2 mM CaCl 2 , pH 7.4 and 2.5 mM probenecid) using an EMBLA 384 plate washer, leaving 30 μL of buffer in each well after the last wash. Loaded cell plates were transferred to the FLIPR and calcium responses were monitored as described below. For quality control, in each compound plate included the reference standards NKA and substance P. Eleven concentrations of the test compounds were evaluated for their ability to increase intracellular calcium levels with respect to the agonist reference standard (NKA or substance P), and the EC 50 value was calculated. The range of final concentrations tested was 0.169 nM to 10 μM, or 1.69 pM to 100 nM, depending on compound potency. Concentration response curves of test compounds were generated in duplicate on at least two different occasions from the same stock solutions. Test solutions were prepared from 10 mM stock solutions in DMSO and 1 μL of each solution was stamped into V-bottom assay plates containing 49 μL assay buffer. The final concentration of DMSO was 0.5% in each well.
Responses were measured as peak fluorescence intensity (FI) minus basal FI and expressed as a percentage of the maximal response induced by NKA for the NK2 receptor, or substance P for the NK1 receptor. Maximal responses to NKA and substance P were calculated by GraphPad Prism v5 concentration response curve fitting (see Data Analysis).
Cyclic AMP stimulation. Four peptides that spanned the range of NK2 receptor agonist potency on the intracellular calcium response (NKA, substance P, [Lys ]-NKA(4-10)) were selected for examination in assays of Gs coupling to NK2 and NK1 receptors to stimulate cyclic AMP (cAMP) production. CHO-hNK2 and CHOhNK1 cells were transiently transfected with a CRE-LUC reporter construct using Lipofectamine 2000. At 24 h post-transfection, cells were plated at a density of 20,000 cells/well in a 96-well culture plate. After 24 h, cells were stimulated with culture medium containing 0.5 mM IBMX and 7 concentrations of the test compounds in the range 0.1 nM-1 μM or 0.19 pM-30 nM, depending on the potency of the compound. Luciferase expression was measured after 5 h of incubation at 37˚C (in the presence of 5% CO 2 ) by adding Firefly Luciferase reagent, followed by Renilla Luciferase reagent. Luminescence was measured by using an Envision Multilabel flash lamp reader after addition of the first and second reagents. Data were normalized by calculating the ratio of the Firefly luminescence from the CRE reporter to the Renilla luminescence from the control Renilla Luciferase vector.
Data analysis
Radioligand binding. Raw data were expressed as total binding (TB), or nonspecific binding (NSB) measured in the presence of excess NKA, septide or substance P. Specific binding (SB) was derived by subtraction of NSB from TB. Saturation experiment curve fitting and K D estimates were performed using Global Fitting Analysis in GraphPad Prism v5 (GraphPad Software Inc, California, USA) by comparing the results of One-Site and Two-Site models to simultaneously fit both TB and NSB (the X axis was radioligand concentration in nM and the Y axis was TB and NSB expressed in dpm or pmol/mg protein). The goodness of fit between One-Site and Two-Site models was examined using Akaike's Information Corrected Criteria (AICC; [23] ) in SAS v9.4 (SAS Institute, Cary NC) in order to select the best model for the data generated. K D and B max were determined by analysis of the saturation data using the Total and Nonspecific Binding equation in GraphPad Prism v5. Data from displacement experiments were plotted as the log [inhibitor concentration] (X axis) versus response expressed as TB in cpm (Y axis). Curve fitting, IC 50 values and Hill slope were determined using a four-parameter logistic model in GraphPad Prism v5. K i value estimates were made using the One Site-fit K i equation in GraphPad Prism v5, by applying the Cheng-Prusoff equation [24] :
is the radioligand concentration in the displacement assay, and K D is the dissociation constant of the radioligand determined in the saturation experiment.
Mean data ± standard deviations (SD) for pIC 50 (-log IC 50 ), slope and pK i (-log of K i ) were calculated from at least two independent experiments with each concentration tested in duplicate. The displacement curves were superimposable with standard deviations less than 0.3.
Functional assays. Agonist concentration response curves were analyzed by GraphPad Prism v5 using a four-parameter logistic equation:
where R is the agonist response, X the agonist concentration, Max and Min are the maximal and the basal effect, EC 50 is the concentration producing 50% of the maximal effect and n is the Hill slope. Results are reported as mean ± SD of the calculated potency value pEC 50 (-log EC 50 ) and % of the maximal effect of the reference standard agonist from at least two independent experiments with each concentration tested in duplicate. ]-NKA(4-10) are shown in Fig 2 and binding affinities of all compounds tested are shown Table 2 .
Results
Affinity
Intracellular calcium response in CHO cells expressing human recombinant NK2 receptors. Both NKA and substance P were full agonists at NK2 receptors as determined by the intracellular calcium response; NKA was approximately 150-fold more potent than substance P (Fig 3; Table 2 ). All test compounds elicited concentration-dependent calcium responses in CHO cells expressing NK2 receptors (Fig 4) . Affinity, potency, efficacy and selectivity of NK2 receptor agonists ]-NKA(4-10) and NKA potently stimulated cAMP production via Gs coupling to NK2 receptors; substance P was the weakest agonist tested (Fig  7; Table 2 ). All four peptides were full agonists. (Fig 8) . Binding data for all compounds tested at the septide site of the human NK1 receptor are shown in Table 3 .
Intracellular calcium response in CHO cells expressing human recombinant NK1 receptors
Both substance P and NKA were full agonists at NK1 receptors in the intracellular calcium assay; substance P was approximately 16-fold more potent than NKA (Fig 10; Table 3 ). All compounds tested elicited concentration-dependent calcium responses and were full agonists at the human NK1 receptor (Fig 4; Table 3 ). Substance P was the most potent agonist with a pEC 50 Cyclic AMP Stimulation in CHO cells expressing human recombinant NK1 receptors. NKA caused the most potent stimulation of cAMP production in CHO cells expressing NK1 receptors, followed by substance P (Fig 12; Table 3 ). [β-Ala ]-NKA(4-10) were notably weaker agonists than NKA and substance P. All compounds tested were full agonists. Affinity, potency, efficacy and selectivity of NK2 receptor agonists ]-NKA(4-10) were more than 28-fold more selective for the human NK2 receptor over the septide site of the NK1 receptor compared with NKA.
Similarly, the ratio of the EC 50 s (in nM) derived from the functional assays was determined. Table 5 lists the agonists in descending selectivity for NK2 over NK1 receptor agonist potency on calcium responses. Consistent with data obtained using radioligand binding assays, the most highly selective NK2 receptor agonists were [Lys ]-NKA(4-10). NKA had marginal selectivity for NK2 receptors, while substance P was selective for activation of NK1 over NK2 receptors (Table 6 ). 
Discussion
To our knowledge, this is the first comparison of amino acid substitutions on the affinity, potency and efficacy of peptide agonists using human recombinant NK2 and NK1 receptors. Consistent with the findings of Chassaing et al [20] and Warner et al [22] using native tissue preparations, the compound with the greatest selectivity for human recombinant NK2 versus NK1 receptors in both radioligand binding and calcium response was [Lys ]-NKA(4-10) were the least selective (NK1/NK2 ratio � 1) and it is striking that NKA had no selectivity for NK2 over NK1 receptors in functional assays measuring calcium responses. Also noteworthy is that the selectivity of these compounds appeared to be lower for calcium responses as compared with the radioligand binding affinities. It is possible that the test compounds may have differential effects on cellular calcium dynamics in native, physiologically relevant, systems and that the recombinant cells used in our study may not be representative of this. Although the kinetics of the calcium response profile differed between NK2 and NK1 receptors (Fig 5) , inspection of FLIPR traces did not reveal any difference in the profile of the calcium rise produced by the tested compounds on NK2 or NK1 receptors, suggesting that their mechanism of action was similar under these assay conditions within the same receptor subtype. The lower selectivity found in calcium response compared with binding affinities may also be related to the presence of subpopulations of receptors coupled to different second messengers. To explore this possibility, a cAMP stimulation assay, via Gs receptor coupling, was also utilized to assess the potency and ]-NKA(4-10), and NKA showed a higher potency in the cAMP stimulation assay compared with the calcium response, their selectivity for NK2 receptors was maintained across the two assays. Interestingly, [β-Ala 8 ]-NKA(4-10) had the greatest selectivity (244-fold) for stimulation of cAMP via activation of NK2 over NK1 receptors, unlike its lower selectivity for calcium response (54-fold). This example of differential effects on second messenger signaling suggests the potential to develop biased NK2 receptor agonists with even greater selectivity in future.
The present studies mainly examined the increase in intracellular calcium levels in response to NK2 and NK1 receptor activation. The rank order of potency to increase calcium response or cAMP production appeared to be similar for activation of NK2 and NK1 receptors. The four compounds tested in the cAMP studies provide a foundation on which to conduct a formal correlation analysis comparing effects of a wider range of compounds on the two second messengers. Under physiological conditions, signal transduction may also involve other second messengers such as inositol phosphate and β-arrestin [26] [27] [28] , and this might result in further differences in the selectivity of compounds for NK2 versus NK1 receptor activation in vivo. Additional studies are needed to characterize the signal transduction pathways activated by agonists acting at NK2 and NK1 receptors in order to determine whether functional selectivity can be further refined.
All compounds behaved as full agonists in the calcium response assays, and four selected compounds were also full agonists in cAMP assays, consistent with the high receptor reserve present in recombinant cell lines [29] . The behavior of [Lys ]-NKA(4-10) as full agonists at human recombinant NK2 receptors is in agreement with functional studies using isolated human colon [1, 4, 30] and bladder [5, 31, 32] . A previous study using human native NK1 receptors expressed by astrocytoma U373 cells also found a linear correlation between displacement of specific [ ]NKA(4-10); [15] ). Functional assays using tissues from other species (rabbit pulmonary artery for NK2 and dog carotid artery for NK1) also found a similar rank order of selectivity for NK2 over NK1 receptors of [β-Ala 8 ]NKA(4-10) >> NKA(4-10) > NKA [25] . Thus, there is good agreement between the findings from the present study using human recombinant receptors and published studies using preparations of human colon, bladder and astrocytoma cells, as well as functional assays from nonhuman species, regarding the relative affinity and efficacy of the agonists tested. 
